0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
In This Issue   |    
In This Issue
Am J Psychiatry 2013;170:A18-A18. doi:10.1176/appi.ajp.2013.17011issue
View Author and Article Information

Copyright © 2013 by the American Psychiatric Association

 
Anchor for JumpAnchor for Jump
Changes in lamotrigine serum levels before and after childbirth require monitoring and incremental dose changes (Clark et al., p. 1240)

Clinical Guidance: Lamotrigine Dosing for Pregnant Bipolar Patients 

Lamotrigine serum levels decline during pregnancy as drug clearance increases. In pregnant women with bipolar disorder, measuring the serum level every 4 weeks and increasing the dose 20%–25% as needed can help maintain the target serum level and reduce bipolar symptoms. After delivery, lamotrigine clearance decreases and toxicity becomes a possibility. Thus, the serum concentration should be measured every 1–2 weeks and the dose reduced incrementally until the prepregnancy serum level is reached. Breast-fed infants should also be monitored for toxicity, as lamotrigine is transferred in breast milk. Clark et al. (p. 1240) highlight the considerable interindividual variation in lamotrigine metabolism in both infant and mother (figure).

Quantitative, diagnosis-independent traits, known as intermediate phenotypes or endophenotypes, may identify more homogeneous patient groups than do psychiatric diagnoses. The Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) examined potential intermediate phenotypes in probands with schizophrenia, bipolar disorder with psychosis, or schizoaffective disorder and in their relatives and healthy subjects. Tamminga et al. (p. 1263) found that symptoms and psychosocial functioning were generally worse in schizophrenia probands than in probands with the other diagnoses, but there was considerable overlap. Likewise, many families contained both schizophrenia and bipolar diagnoses. Hill et al. (p. 1275) report increasingly severe cognitive impairment from bipolar disorder to schizoaffective disorder to schizophrenia. Family rates of cognitive deficits were comparable in schizophrenia and bipolar disorder, but in bipolar disorder the deficits mainly affected relatives with cluster A or cluster B personality traits. Measurements of gray matter volume by Ivleva et al. (p. 1285) showed differences between psychotic and nonpsychotic individuals and between diagnoses: schizophrenia and schizoaffective probands had overlapping areas of low gray matter volume in numerous cortical and subcortical regions, whereas bipolar probands had fewer low-volume areas. The editorial by Frangou (p. 1223) notes that structural imaging reflects the static brain configuration, whereas cognitive performance is an expression of a dynamic configuration.

Clinical Guidance: Antidepressant Use in Bipolar Disorder 

Antidepressants should be prescribed for bipolar I patients only as an adjunct to mood-stabilizing medication, since antidepressant-related mood elevations are more common in bipolar I than bipolar II disorder. Serotonin reuptake inhibitors and bupropion appear to be less likely to trigger a mania switch than tricyclics and norepinephrine-serotonin reuptake inhibitors. Maintenance treatment with adjunctive antidepressants may be considered if a patient becomes depressed after acute treatment ends. Bipolar patients beginning antidepressant treatment should be closely monitored for mania symptoms. Pacchiarotti et al. (p. 1249) present a task force report but note that evidence is still limited.

Clinical Guidance: Personalizing Panic Disorder Treatment 

Many patients diagnosed as having panic disorder with agoraphobia benefit from cognitive-behavioral therapy (CBT) even if they do not respond fully, but functional brain imaging provides clues about who is likely to improve most. Lueken et al. (p. 1345) compared pretreatment responses to a fear-conditioning task in CBT responders and nonresponders. Nonresponders had greater neural responses to a safety signal, raising the possibility that CBT may not be as effective for patients with a bias toward detecting threat. Successful treatment was associated with a posttreatment increase in hippocampal activation during processing of stimulus contingencies. This suggests awareness of stimulus-outcome associations, another quality that may help identify patients who will benefit the most from CBT. Editorialist Henn (p. 1235) cites deep brain stimulation for depression as an example of how knowledge of brain circuits can inform treatment.

Changes in lamotrigine serum levels before and after childbirth require monitoring and incremental dose changes (Clark et al., p. 1240)
+

References

+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe